ALS Cure Roadmap is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research.
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease characterized by the selective loss of upper and lower motor neurons. Despite decades of research, no cure exists—but a comprehensive therapeutic roadmap is emerging from converging advances in genetics, molecular biology, and clinical trial design. This page maps the landscape of therapeutic approaches, current clinical trials, and future directions toward disease modification and ultimately a cure.
¶ Current Therapeutic Landscape
Three drugs have received regulatory approval for ALS:
| Drug |
Mechanism |
Approval Year |
Effect |
| Riluzole |
Glutamate antagonism, anti-excitotoxicity |
1995 (FDA) |
~2-3 month survival benefit |
| Edaravone |
Antioxidant, reduces oxidative stress |
2017 (FDA) |
Slows functional decline |
| Sodium Phenylbutyrate/Taurursodiol (Relyvrio) |
Reduces neuronal death |
2022 (FDA) |
~2.5 month survival benefit |
These modest benefits underscore the need for more potent disease-modifying therapies. Riluzole was the first FDA-approved disease-modifying drug for ALS, establishing the principle that pharmacological intervention could alter disease course.
Approximately 10-15% of ALS cases are familial, with identified causative mutations providing actionable therapeutic targets:
flowchart TD
A["Genetic Causes"] --> B["C 9orf72"]
A --> C["S OD1"]
A --> D["T ARDBP"]
A --> E["F US"]
A --> G["A LSIN"]
A --> H["U BQLN2"]
B --> B1["Antisense Oligos<br/>Gene Silencing"]
B --> B2["Repeat Expansion<br/>Targeting"]
C --> C1["AS Os<br/>Bunodimod"]
C --> C2 ["Protein Stabilizers"]
D --> D1AS ["Os"]
D --> D2 ["Autophagy Modulators"]
E --> E1AS ["Os"]
E --> E2["RN A Processing<br/>Modulators"]
- Hexanucleotide repeat expansion is the most common genetic cause
- Two pathological mechanisms: toxic gain-of-function (RNA foci, dipeptides) and haploinsufficiency
- ASO therapies targeting C9orf72 are in clinical trials
- WAVE Life Sciences and Ionis Pharmaceuticals have active programs
- Over 150 mutations identified; A4V is most aggressive in North America
- Tofersen (Bioport/Biogen) — ASO targeting SOD1 — showed biomarker reduction and potential clinical benefit in the VALOR trial
- Tofersen received FDA approval in 2023
¶ TARDBP (TDP-43) and FUS
- Protein aggregates in >95% of ALS cases (TDP-43) make these attractive targets
- ASO programs targeting TARDBP and FUS are in preclinical/early clinical stages
Impaired RNA processing and protein homeostasis are central to ALS pathogenesis:
- RNA metabolism defects: Abnormal splicing, transport, and translation
- Proteostasis failure: Impaired ubiquitin-proteasome system and autophagy
- Stress granule dysregulation: Aberrant stress granule formation and clearance
See: ALS RNA Metabolism and Proteostasis Failure
Microglial activation and peripheral immune infiltration drive disease progression:
- Pro-inflammatory cytokines: TNF-α, IL-1β, IL-6 elevated in ALS
- Complement system activation contributes to motor neuron injury
- Regulatory approaches: Anti-inflammatory agents in clinical trials
Energy failure and oxidative stress are therapeutic targets:
- Edaravone (approved) scavenges reactive oxygen species
- CoQ10 and idebenone have been tested in clinical trials
- Mitochondrial biogenesis activators in development
- Neurotrophic factors: BDNF, GDNF, CNTF delivery approaches
- Axon regeneration: Neurotrophin mimetics
- Calcium homeostasis: Calcium channel modulators
- Astrocytes: Toxicity transmission, support restoration
- Microglia: Pro-/anti-inflammatory modulation
- Oligodendrocytes: Demyelination, metabolic support
- Synaptic stabilization: Pre- and post-synaptic targets
- Muscle-endplate protection: Anti-apoptotic approaches
¶ Clinical Trial Landscape
| Trial |
Drug |
Target |
Status |
Outcome |
| CENTAUR |
AMX0035 (relyvrio) |
Pan-caspase, oxidative stress |
Completed |
FDA approved |
| VALOR |
Tofersen |
SOD1 |
Completed |
Biomarker success |
| HEALEY |
Multiple |
Various |
Platform trial |
Ongoing |
| PHOENIX |
NurOwn (MSC-NTF) |
Neurotrophic factors |
Completed |
Negative |
| ATLAS |
BIIB067 (tofersen) |
Pre-symptomatic SOD1 |
Ongoing |
Preventive |
- CytoPedia: Cell therapy platforms
- Gene therapy vectors: AAV delivery of therapeutic genes
- Antisense oligonucleotides: Multiple programs targeting different mutations
Patient stratification using biomarkers is transforming trial design:
- Neurofilament light chain (NfL): Blood biomarker for disease activity
- Genetic testing: Enriching trials for specific mutations
- Neuroimaging: PET and MRI biomarkers
flowchart LR
A["Gene Identification"] --> B["Target Validation"]
B --> C["Modality Selection"]
C --> D["AAV Gene Therapy"]
C --> E["Antisense Oligonucleotides"]
C --> F["CRISPR Gene Editing"]
D --> G["CNS Delivery"]
E --> G
F --> G
G --> H["Preclinical Models"]
H --> I["Clinical Trials"]
I --> J["Biomarker-Guided Dosing"]
J --> K["Disease Modification"]
- AAV vectors: Cross blood-brain barrier with appropriate serotypes
- Antisene oligonucleotides: Direct injection or systemic delivery
- CRISPR-based approaches: In vivo editing showing promise in preclinical models
- Mesenchymal stem cells (MSCs): Neurotrophic factor secretion
- iPSC-derived motor neurons: Replacement therapy
- Glial progenitors: Support cell restoration
- Protein-protein interaction inhibitors: Prevent aggregate formation
- Autophagy enhancers: Clear toxic protein aggregates
- RNA splicing modulators: Correct abnormal splicing
- Genetic status: C9orf72, SOD1, TARDBP, FUS
- Age of onset: Strong prognostic factor
- Site of onset: Bulbar vs. limb
- Target engagement: Reduction in toxic protein/RNA
- Biomarker modulation: NfL changes as treatment response indicator
¶ Challenges and Solutions
ALS is clinically and genetically heterogeneous. Solutions:
- Precision medicine approaches: Mutation-specific therapies
- Biomarker stratification: Enriching trials with likely responders
- Subgroup analysis: Identifying responsive populations
No robust prognostic biomarker exists. Current efforts:
- Multi-modal biomarkers: Combining fluid, imaging, and clinical measures
- Digital biomarkers: Wearable devices for continuous monitoring
- Machine learning: Integrated biomarker panels
Traditional trial designs are slow and expensive. Solutions:
- Platform trials: Master protocols testing multiple therapies
- Adaptive designs: Interim analyses and sample size re-estimation
- Pre-symptomatic trials: Treating before irreversible loss
- Expand genetic testing: Identify all at-risk individuals
- Biomarker validation: NfL as regulatory-accepted endpoint
- Gene-specific ASOs: C9orf72, TARDBP, FUS programs advance
- Platform trials: Multiple agents tested simultaneously
- Combination therapies: Multi-target approaches
- Gene editing: In vivo CRISPR reaches clinical trials
- Cell replacement: iPSC-derived motor neurons in trials
- Personalized medicine: Mutation-specific treatment algorithms
- Disease prevention: Pre-symptomatic intervention for genetic cases
- Functional cure: Sustained disease modification
- Regeneration: Motor neuron replacement and functional recovery
- ALS Association: Research funding and patient advocacy
- NEIDECS Consortium: European ALS research network
- ALS Clinical Trials Consortium: Multi-site trial coordination
- Massachusetts General Hospital: ALS Clinic
- University of Pennsylvania: ALS Center
- Stanford Neuroscience Health Center: ALS Program
The path to an ALS cure requires a multi-pronged approach targeting the disease's complex biology. The convergence of genetic insights, biomarker development, and novel therapeutic modalities offers unprecedented hope. While significant challenges remain, the current pipeline—with over 100 clinical trials globally and multiple promising modalities in development—represents the most robust therapeutic effort in ALS history.
Success will require continued investment, international collaboration, and the integration of precision medicine principles into clinical trial design. The roadmap outlined here provides a framework for coordinating these efforts toward the ultimate goal: a cure for ALS.